OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
HANNM55

Mukdahan International Hospital PCL

Healthcare Facilities & ServicesVerified

Mukdahan International Hospital PCL has a capital structure with 560 million basic and diluted shares outstanding, indicating no dilution from stock options or convertible instruments. The company reported free cash flow of 7.3 million THB in the latest period, but liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's profitability is modest, with a net income of 1.98 million THB and an operating income of 3.93 million THB. Gross profit of 31.63 million THB suggests a relatively low-margin business model, which is typical for healthcare facilities. However, without industry-specific metrics or cohort medians, a direct comparison to industry benchmarks is not possible. Geographic and segment exposure is not disclosed in the available data, but the company operates as a single entity in Thailand. Revenue concentration in a single geographic market may expose the company to local economic and regulatory risks. Growth trajectory is not clearly defined in the available data, as no forward-looking revenue guidance or historical growth rates are provided. The company reported revenue of 115.99 million THB in the latest period, but without prior-year data, it is not possible to assess year-over-year growth. Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and the absence of going-concern language in source documents. Dilution risk is currently low, as basic and diluted shares are equal, and no adjustments were applied to the valuation. Recent events or filings are not disclosed in the available data, and no transcripts or earnings call summaries are provided to assess management commentary or strategic direction.

30-day price · HANNM(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyMukdahan International Hospital PCL
TickerHANNM.BK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Mukdahan International Hospital PCL operates in the healthcare facilities and services industry, providing medical services and hospital care in Thailand.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92.

Mukdahan International Hospital PCL has a capital structure with 560 million basic and diluted shares outstanding, indicating no dilution from stock options or convertible instruments. The company reported free cash flow of 7.3 million THB in the latest period, but liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's profitability is modest, with a net income of 1.98 million THB and an operating income of 3.93 million THB. Gross profit of 31.63 million THB suggests a relatively low-margin business model, which is typical for healthcare facilities. However, without industry-specific metrics or cohort medians, a direct comparison to industry benchmarks is not possible. Geographic and segment exposure is not disclosed in the available data, but the company operates as a single entity in Thailand. Revenue concentration in a single geographic market may expose the company to local economic and regulatory risks. Growth trajectory is not clearly defined in the available data, as no forward-looking revenue guidance or historical growth rates are provided. The company reported revenue of 115.99 million THB in the latest period, but without prior-year data, it is not possible to assess year-over-year growth. Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and the absence of going-concern language in source documents. Dilution risk is currently low, as basic and diluted shares are equal, and no adjustments were applied to the valuation. Recent events or filings are not disclosed in the available data, and no transcripts or earnings call summaries are provided to assess management commentary or strategic direction.
Key takeaways
  • The company has no dilution risk as basic and diluted shares are equal.
  • Free cash flow is positive but relatively small at 7.3 million THB.
  • Profitability is low, with a net income of 1.98 million THB and a low-margin business model.
  • Liquidity risk could not be assessed due to missing balance-sheet data.
  • Revenue concentration in a single geographic market may increase exposure to local economic and regulatory risks.
  • No forward-looking guidance or historical growth data is available to assess growth trajectory.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyTHB
Revenue$116.0M
Gross profit$31.6M
Operating income$3.9M
Net income$2.0M
R&D
SG&A
D&A
SBC
Operating cash flow$14.4M
CapEx-$4.5M
Free cash flow$7.3M
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$511.9M$105.6M-$3.4M$94.3M
FY-3$487.9M$30.6M-$2.7M$11.6M
FY-2$527.1M$46.5M$27.8M$49.4M
FY-1$492.5M$30.7M$21.2M$24.1M
FY0$463.1M$17.6M$22.0M$45.7M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$429.1M$91.9M$73.7M
FY-3$375.4M$171.3M$21.4M
FY-2$345.2M$176.8M$38.0M
FY-1$333.0M$189.4M$15.4M
FY0$423.8M$301.7M$121.7M
PeriodOCFCapExFCFSBC
FY-4$97.4M-$28.7M$94.3M
FY-3$73.5M-$49.1M$11.6M
FY-2$103.4M-$22.7M$49.4M
FY-1$45.0M-$37.2M$24.1M
FY0$55.9M-$17.4M$45.7M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$116.0M$3.9M$2.0M$7.3M
FQ-6$122.8M$8.1M$5.8M$8.6M
FQ-4$121.3M$6.8M$4.7M$4.1M
FQ-3$120.7M$13.0M$20.2M$26.9M
FQ-2$114.4M$1.4M$470.7k$6.3M
FQ-1$121.6M$5.5M$3.7M$9.9M
FQ0$106.4M-$2.2M-$2.4M$2.6M
FQ-5$132.4M$11.8M$8.8M$4.2M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
FQ-5
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-4
FQ-3$336.5M$205.4M$24.4M
FQ-2$321.8M$191.2M$7.9M
FQ-1$442.9M$304.1M$116.9M
FQ0$423.8M$301.7M$121.7M
FQ-5
PeriodOCFCapExFCFSBC
FQ-7$14.4M-$4.5M$7.3M
FQ-6$17.8M-$11.5M$8.6M
FQ-4$45.0M-$37.2M$4.1M
FQ-3$24.8M-$3.4M$26.9M
FQ-2$29.2M-$7.9M$6.3M
FQ-1$30.8M-$12.2M$9.9M
FQ0$55.9M-$17.4M$2.6M
FQ-5$32.0M-$26.1M$4.2M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion7.3%
CapEx/Revenue-3.9%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Biotechnology · cohort 117 companies
MetricHANNMActivity
Op margin3.4%5.6% medp25 -4.2% · p75 12.6%below median
Net margin1.7%2.8% medp25 -3.4% · p75 8.8%below median
Gross margin27.3%36.5% medp25 23.7% · p75 65.2%below median
CapEx / revenue-3.9%-4.9% medp25 -11.5% · p75 -2.0%above median
Debt / equity69.3% medp25 7.9% · p75 120.9%
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-09 09:36 UTC#c8c9e1a3
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 02:30 UTCJob: 5d9c18fd